$GILD News

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For

"California Supreme Court Rules In Favor Of Gilead Sciences In 'Duty To Innovate' Case Involving HIV Drugs" - Reuters

Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Do Wall Street Analysts Like Gilead Sciences Stock?

Gilead (GILD) Stock Stays Cheap On Its 130% Five Year Run

Gilead Sciences (GILD) Following Trodelvy Progress And A Fair Value Debate

BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $145

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $165

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors

CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast Cancer

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

Gilead Sciences' Quarterly Earnings Preview: What You Need to Know